Middle East & Africa Cardiac Biomarkers Market Size & Outlook
The cardiac biomarkers market in Middle East & Africa is expected to reach a projected revenue of US$ 1,360.6 million by 2033. A compound annual growth rate of 5.7% is expected of Middle East & Africa cardiac biomarkers market from 2026 to 2033.
The MEA cardiac biomarkers market generated a revenue of USD 874.0 million in 2025.
The market is expected to grow at a CAGR of 5.7% from 2026 to 2033.
In terms of segment, troponin was the largest revenue generating type in 2025.
Troponin is the most lucrative type segment registering the fastest growth during the forecast period.
Country-wise, UAE is expected to register the highest CAGR from 2026 to 2033.
MEA data book summary
Market revenue in 2025
USD 874.0 million
Market revenue in 2033
USD 1,360.6 million
Growth rate
5.7% (CAGR from 2026 to 2033)
Largest segment
Troponin
Fastest growing segment
Troponin
Historical data covered
2021 - 2024
Base year for estimation
2025
Forecast period covered
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
CK-MB, Myoglobin, Troponin, BNP and NT-proBNP
Key market players worldwide
Abbott Laboratories, QuidelOrtho Corp, Siemens Healthineers AG ADR, Roche Holding AG ADR, Danaher Corp, BioMerieux SA, Bio-Rad Laboratories Inc, Randox, Creative Diagnostics, Life Diagnostics
Other key industry trends
In terms of revenue, MEA region accounted for 4.2% of the global cardiac biomarkers market in 2025.
Globally, North America is projected to lead the regional market in terms of revenue in 2033.
Asia Pacific is the fastest growing regional market and is projected to reach USD 12,660.4 million by 2033.
According to the data from the World Health Organization (WHO), an estimated three-quarters of the global mortality stemming from CVDs occur in low and middle-income countries. In Africa, CVDs in the form of heart attacks and heart failure are common. Recent developments in health research conducted on the African continent have led to improvements in the detection and treatment of cardiac disorders.
Optimization of resources and the implementation of new healthcare systems are expected to rise, which is expected to benefit the cardiac diagnostics area, especially the development of cardiac biomarkers used for the detection and evaluation of cardiac diseases.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cardiac Biomarkers Market Outlook will help companies and investors design strategic landscapes.
Troponin was the largest segment with a revenue share of 38.24% in 2025.
Horizon Databook has segmented the Middle East & Africa cardiac biomarkers market based on ck-mb, myoglobin, troponin, bnp and nt-probnp covering the revenue growth of each sub-segment from 2021 to 2033.
According to the data from the World Health Organization (WHO), an estimated three-quarters of the global mortality stemming from CVDs occur in low and middle-income countries. In Africa, CVDs in the form of heart attacks and heart failure are common. Recent developments in health research conducted on the African continent have led to improvements in the detection and treatment of cardiac disorders.
Optimization of resources and the implementation of new healthcare systems are expected to rise, which is expected to benefit the cardiac diagnostics area, especially the development of cardiac biomarkers used for the detection and evaluation of cardiac diseases.
Middle East & Africa Cardiac Biomarkers Market Type Outlook (Revenue, USD Million , 2021-2033)
Troponin
CK-MB
Myoglobin
BNP and NT-proBNP
Others
Middle East & Africa Cardiac Biomarkers Market Application Outlook (Revenue, USD Million , 2021-2033)
Acute Coronary Syndrome
Myocardial Infarction
Congestive Heart Failure
Others
Middle East & Africa Cardiac Biomarkers Market End Use Outlook (Revenue, USD Million , 2021-2033)
Laboratory Testing
Point of Care Testing
Reasons to subscribe to cardiac biomarker market databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of cardiac biomarker market databook
Our clientele includes a mix of cardiac biomarker market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa cardiac biomarker market, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa cardiac biomarker market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Middle East Africa Cardiac Biomarkers Market, 2021-2033 (US$M)